Alliance for Regenerative Medicine

This week, a new groundbreaking report published by the Office of Health Economics and ARM Member Cell and Gene Therapy Catapult shows that cell and gene therapy drives substantial economic benefits. The study, which analyzed treatments for acute lymphoblastic leukemia, acute myeloid leukemia, beta-thalassemia, and Alzheimer’s disease, found that medical intervention with new therapies could potentially save healthcare systems hundreds of millions to billions of pounds. Additionally, durable CGT treatments for the diseases analyzed showed notable quantifiable societal benefits. We commend the authors for pioneering an evaluation model demonstrating the value of cell and gene therapy. Read it here: https://lnkd.in/eGDdTXwN #cellandgenetherapy

Join the Alliance for Regenerative Medicine in Washington, DC, for our upcoming "Evolution of the Cell & Gene Therapy Sector" workshop in partnership with InspiroGene by McKesson, Danaher Corporation, and Charles River Laboratories. Gather with industry leaders, regulators, clinicians, and patient advocates to explore the next phase of the cell and gene therapy (CGT) sector. This two-day program will dive into the scientific, regulatory, and patient access challenges shaping the field, focusing on scaling advanced therapies to reach more patients worldwide. Learn more, see the agenda, and register below. ➡️ https://lnkd.in/e9bJeniW #cellandgenetherapy

Check out Jonathan D. Grinstein, PhD's take on growing momentum for cell and gene therapy based on his reporting from ARM’s recent Meeting on the Mesa for Inside Precision Medicine. He includes highlights of ARM’s ‘Reasons to Believe’ in CGT and promising medicines under development by ARM members Trogenix and Prime Medicine, Inc. https://lnkd.in/eCvhmmZ5 #CGMesa25 #cellandgenetherapy

A touching op-ed from the Co-Founder of the CureLGMD2i Foundation on how the dreams of her daughter and many other children with rare diseases depend on the reauthorization of the FDA's Rare Pediatric Disease Priority Review Voucher (PRV) Program. This vital program accelerates innovation in developing treatments, such as cell and gene therapies, to help treat and potentially cure rare diseases in children. However, its fate is currently stalled in Congress. We join Kelly in calling on Congress to swiftly reauthorize the PRV Program by passing the Give Kids a Chance Act before the end of the year.

Solid tumors have been a challenge for modern medicine. However, the cell and gene therapy clinical pipeline is advancing potential breakthroughs. ARM's Stephen Majors sat down with Ken Macnamara, CEO of Trogenix, at ARM Studios during #CGMesa25 to highlight their precision genetic medicine, which is now entering the clinic and looking to be a transformative option for patients who face a terminal prognosis with glioblastoma.

Looking to reshare your favorite moments from ARM's 2025 Cell & Gene Meeting on the Mesa? Conference photos can now be accessed through our Flickr account. 📸 ➡️ https://lnkd.in/efTSBYvE Attendees, speakers, and presenters are welcome to download photos of their favorite moments to share on social media. The photos are organized in albums by each day of the conference. #CGMesa25

The regulatory picture for cell and gene therapy in 2026 continues to take form. Two more BLAs by the FDA were accepted, setting up new PDUFA dates in the spring of next year. 🧬 March 28, 2026 | Kresladi Rocket Pharmaceuticals' gene therapy to treat severe leukocyte adhesion deficiency type 1 https://lnkd.in/e_-2R7nm 🧪 April 6, 2026 | Orca-T Orca Bio's T-cell therapy to treat acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes https://lnkd.in/e2PcDsKW Four PDUFA dates are currently scheduled in 2026, with more therapies poised to advance in the pipeline. To learn more, look out for ARM's Q3 2025 Sector Snapshot this month.

This year’s Cell & Gene Meeting on the Mesa brought together leading investors and analysts to discuss the evolving dynamics between the cell and gene therapy sector and capital markets. ARM CEO Tim Hunt had the opportunity to sit down with Samantha Semenkow, Ph.D., Vice President, SMid Biotech Equity Research Analyst at Citi, at ARM Studios to unpack some of the themes and trends highlighted at the conference. #CGMesa25

And that’s a wrap for ARM's 2025 Cell and Gene Meeting on the Mesa. And what a week it was! Thanks to our sponsors, speakers, and partners for making this year’s Meeting on the Mesa possible, and to our amazing patient advocates for sharing their inspirational stories. Did you miss out on any panels or workshops you wanted to see? Attendees can rewatch any session through the online conference platform. Also, keep an eye out for more ARM Studios interviews with sector leaders in the coming weeks. 🎥 Safe travels, and see you next year! 🌵🧬 #CGMesa25